www.vabysmo-hcp.com Open in urlscan Pro
2606:4700::6812:223  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip To Main Content
Prescribing Information Prescribing Information Important Safety Information
Important Safety Information Contact Genentech Contact Genentech For Patients &
Caregivers For Patients & Caregivers
MENU

   
 * HOW VABYSMO WORKS
 * nAMD
    * Dosing & Study Design
    * Clinical Data

 * DME
    * Dosing & Study Design
    * Clinical Data

 * RVO
    * Dosing & Study Design
    * Clinical Data

 * SAFETY
 * FINANCIAL SUPPORT & RESOURCES
 * EXPERT PERSPECTIVE VIDEOS
   

Prescribing Information Important Safety Information Contact Genentech For
Patients & Caregivers

nAMD Data
DME Data
RVO Data
Financial Support & Resources


VABYSMO® (FARICIMAB-SVOA) IS THE FIRST AND ONLY DUAL-PATHWAY TREATMENT FOR NAMD,
DME, AND RVO2*


POWERFUL FIRST-LINE
EFFICACY2

VABYSMO met its primary endpoint of non-inferiority vs aflibercept 2 mg in the
mean change from baseline in BCVA across nAMD, DME, and RVO2†


RAPID AND SUSTAINED
DRYING1,3,4

VABYSMO achieved CST reductions in all 3 indications over 2 years in DME, 1 year
in nAMD, and 6 months in RVO1,3,4‡


FLEXIBLE 1–4 MONTH
DOSING2

Extended dosing intervals driven by CST and visual acuity in nAMD and DME2§

Monthly dosing for 6 months in RVO2


POWERFUL
FIRST-LINE EFFICACY2

VABYSMO met its primary endpoint of non-inferiority vs aflibercept 2 mg in the
mean change from baseline in BCVA across nAMD, DME, and RVO2†


RAPID AND
SUSTAINED DRYING1,3,4

VABYSMO achieved CST reductions in all 3 indications over 2 years in DME, 1 year
in nAMD, and 6 months in RVO1,3,4‡


FLEXIBLE 1–4
MONTH DOSING2

Extended dosing intervals driven by CST and visual acuity in nAMD and DME2§

Monthly dosing for 6 months in RVO2

*Macular edema following retinal vein occlusion (RVO).

†Primary endpoint was measured by the ETDRS letter score and tested for
non-inferiority using a margin of 4 letters. nAMD: VABYSMO met its primary
endpoint of non-inferiority at year 1 (avg. of weeks 40, 44, and 48).
Differences in LS means for VABYSMO were +0.7 letters (CI: [95%] -1.1, +2.5) in
TENAYA; and 0.0 letters (CI: [95%] -1.7, +1.8) in LUCERNE. DME: VABYSMO met its
primary endpoint of non-inferiority at year 1 (avg. of weeks 48, 52, and 56).
Differences in LS means in YOSEMITE were +0.7 letters (CI: [97.5%] -1.1, +2.5)
for VABYSMO Q4W–Q16W and -0.2 letters (CI: [97.5%] -2.0, +1.6) for VABYSMO Q8W.
Differences in LS means in RHINE were +0.5 letters (CI: [97.5%] -1.1, +2.1) for
VABYSMO Q4W–Q16W and +1.5 letters (CI: [97.5%] -0.1, +3.2) for VABYSMO Q8W. A
non-inferiority margin was not available for year 2. RVO: VABYSMO met its
primary endpoint of non-inferiority at week 24. Differences in LS means for
VABYSMO were -0.6 letters (CI: [95%] -2.2, +1.1) in BALATON; and -0.4 letters
(CI: [95%] -2.5, +1.6) in COMINO.2

‡Reduction in CST over time was a prespecified secondary endpoint. Reductions in
CST were observed across all treatment arms throughout the six Phase 3 studies
in nAMD, DME, and RVO.2

§Recommended dosing is 4 or 6 (DME only) monthly loading doses followed by 1–4
month dosing in nAMD and DME.2




IMPORTANT SAFETY INFORMATION & INDICATIONS

Back to Top

INDICATIONS

VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF)
inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of
patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD),
Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion
(RVO).


IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VABYSMO is contraindicated in patients with ocular or periocular infection, in
patients with active intraocular inflammation, and in patients with known
hypersensitivity to faricimab or any of the excipients in VABYSMO.
Hypersensitivity reactions may manifest as rash, pruritus, urticaria, erythema,
or severe intraocular inflammation.


WARNINGS AND PRECAUTIONS

ENDOPHTHALMITIS AND RETINAL DETACHMENTS

Intravitreal injections have been associated with endophthalmitis and retinal
detachments. Proper aseptic injection techniques must always be used when
administering VABYSMO. Patients should be instructed to report any symptoms
suggestive of endophthalmitis or retinal detachment without delay, to permit
prompt and appropriate management.


INCREASE IN INTRAOCULAR PRESSURE

Transient increases in intraocular pressure (IOP) have been seen within 60
minutes of intravitreal injection, including with VABYSMO. IOP and the perfusion
of the optic nerve head should be monitored and managed appropriately.

THROMBOEMBOLIC EVENTS

Although there was a low rate of arterial thromboembolic events (ATEs) observed
in the VABYSMO clinical trials, there is a potential risk of ATEs following
intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke,
nonfatal myocardial infarction, or vascular death (including deaths of unknown
cause).

The incidence of reported ATEs in the nAMD studies during the first year was 1%
(7 out of 664) in patients treated with VABYSMO compared with 1% (6 out of 662)
in patients treated with aflibercept.

The incidence of reported ATEs in the DME studies from baseline to week 100 was
5% (64 out of 1,262) in patients treated with VABYSMO compared with 5% (32 out
of 625) in patients treated with aflibercept.

The incidence of reported ATEs in the RVO studies during the first 6 months was
1.1% (7 out of 641) in patients treated with VABYSMO compared with 1.4% (9 out
of 635) in patients treated with aflibercept.

RETINAL VASCULITIS AND/OR RETINAL VASCULAR OCCLUSION

Retinal vasculitis and/or retinal vascular occlusion, typically in the presence
of intraocular inflammation, have been reported with the use of VABYSMO.
Healthcare providers should discontinue treatment with VABYSMO in patients who
develop these events. Patients should be instructed to report any change in
vision without delay.


ADVERSE REACTIONS

The most common adverse reactions (≥5%) reported in patients receiving VABYSMO
were cataract (15%) and conjunctival hemorrhage (8%).


PREGNANCY, LACTATION, FEMALES AND MALES OF REPRODUCTIVE POTENTIAL

Based on the mechanism of action of VEGF and Ang-2 inhibitors, there is a
potential risk to female reproductive capacity, and to embryo-fetal development.
VABYSMO should not be used during pregnancy unless the potential benefit to the
patient outweighs the potential risk to the fetus. The developmental and health
benefits of breastfeeding should be considered along with the mother’s clinical
need for VABYSMO and any potential adverse effects on the breastfed child from
VABYSMO. Females of reproductive potential are advised to use effective
contraception prior to the initial dose, during treatment and for at least 3
months following the last dose of VABYSMO.

You may report side effects to the FDA at (800) FDA-1088 or
www.fda.gov/medwatch. You may also report side effects to Genentech at (888)
835-2555.

Please see additional Important Safety Information in the full VABYSMO
Prescribing Information.



References

 * * Data on file. South San Francisco, CA: Genentech, Inc.
     
     Data on file. South San Francisco, CA: Genentech, Inc.
   
   * VABYSMO [package insert]. South San Francisco, CA: Genentech, Inc; 2023.
     
     VABYSMO [package insert]. South San Francisco, CA: Genentech, Inc; 2023.
   
   * Regula JT, et al. EMBO Mol Med. 2016;8:1265-1288.
     
     Regula JT, et al. EMBO Mol Med. 2016;8:1265-1288.
   
   * Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661.
     
     Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635-661.
   
   * Fiedler U, et al. Trends Immunol. 2006;27(12):552-558.
     
     Fiedler U, et al. Trends Immunol. 2006;27(12):552-558.
   
   * Hawighorst T, et al. American Journ of Pathol. 2002;160(4):1381-1392.
     
     Hawighorst T, et al. American Journ of Pathol. 2002;160(4):1381-1392.
   
   * Avery RL, et al. Presented at American Association of Ophthalmology (AAO)
     2022. Sept 30-Oct 03 2022.
     
     Avery RL, et al. Presented at American Association of Ophthalmology (AAO)
     2022. Sept 30-Oct 03 2022.
   
   * Heier J, et al. Lancet. 2022;399(10326):729-740.
     
     Heier J, et al. Lancet. 2022;399(10326):729-740.
   
   * Guymer R, et al. Presented at Angiogenesis, Exudation, and Degeneration
     2022. Feb 11-12 2022.
     
     Guymer R, et al. Presented at Angiogenesis, Exudation, and Degeneration
     2022. Feb 11-12 2022.
   
   * Wykoff C, et al. Lancet. 2022;399(10326):741-755.
     
     Wykoff C, et al. Lancet. 2022;399(10326):741-755.
   
   * Heier JS, et al. Presented at American Academy of Ophthalmology Retina
     Subspecialty Day (AAO-SSD) 2021. Nov 12-13 2021.
     
     Heier JS, et al. Presented at American Academy of Ophthalmology Retina
     Subspecialty Day (AAO-SSD) 2021. Nov 12-13 2021.
   
   * Goldberg R, et al. Presented at the Association for Research in Vision and
     Ophthalmology (ARVO) 2023. April 23-27 2023.
     
     Goldberg R, et al. Presented at the Association for Research in Vision and
     Ophthalmology (ARVO) 2023. April 23-27 2023.
   
   * Baumal CR, et al. Presented at the Association for Research in Vision and
     Ophthalmology (ARVO) 2022. May 1-4 2022.
     
     Baumal CR, et al. Presented at the Association for Research in Vision and
     Ophthalmology (ARVO) 2022. May 1-4 2022.
   
   * Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964-972.
     
     Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964-972.
   
   * Sahni J, et al. Ophthalmology. 2019;126(8):1155-1170.
     
     Sahni J, et al. Ophthalmology. 2019;126(8):1155-1170.
   
   * Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964-972.
     
     Khanani AM, et al. JAMA Ophthalmol. 2020;138(9):964-972.
   
   * Sahni J, et al. Ophthalmology. 2019;126(8):1155-1170.
     
     Sahni J, et al. Ophthalmology. 2019;126(8):1155-1170.
   
   * Goldberg R, et al. Presented at the Association for Research in Vision and
     Ophthalmology (ARVO) 2023. April 23-27 2023.
     
     Goldberg R, et al. Presented at the Association for Research in Vision and
     Ophthalmology (ARVO) 2023. April 23-27 2023.
   
   * Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration
     2023. Feb 10-11 2023.
     
     Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration
     2023. Feb 10-11 2023.

 * * Baumal CR, et al. Presented at American Academy of Ophthalmology (AAO)
     2022. Sep 30-Oct 03 2022.
     
     Baumal CR, et al. Presented at American Academy of Ophthalmology (AAO)
     2022. Sep 30-Oct 03 2022.
   
   * Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration
     2023. Feb 10-11 2023.
     
     Tadayoni R, et al. Presented at Angiogenesis, Exudation, and Degeneration
     2023. Feb 10-11 2023.



Contact Us Privacy Policy Terms & Conditions Accessibility Your Privacy Choices
Site Map

© 2024 Genentech USA, Inc. All rights reserved. This site is intended for U.S.
residents only.


Close
Video Player is loading.
Play Video
PlaySkip Backward
Mute

Current Time 0:00
/
Duration 0:15
Loaded: 64.77%


0:00
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -0:15
 
Share
1x
Playback Rate

Chapters
 * Chapters

Descriptions
 * descriptions off, selected

Captions
 * captions settings, opens captions settings dialog
 * captions off, selected

Audio Track
 * en (Main), selected

Fullscreen

This is a modal window.



Beginning of dialog window. Escape will cancel and close the window.

TextColorWhiteBlackRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-TransparentText
BackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityOpaqueSemi-TransparentTransparentCaption
Area
BackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanOpacityTransparentSemi-TransparentOpaque
Font Size50%75%100%125%150%175%200%300%400%Text Edge
StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional
Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall
Caps
Reset restore all settings to the default valuesDone
Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or
activating the close button.


Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or
activating the close button.






LINK TO HEALTHCARE PROFESSIONALS SITE

Close

The information contained in this section of the site is intended for U.S.
healthcare professionals only. Click "OK" if you are a healthcare professional.

Close
OK



LINK TO THIRD PARTY SITE

Close

The link you have selected will take you away from this site to one that is not
owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation
as to the accuracy of the information contained on sites we do not own or
control. Genentech does not recommend and does not endorse the content on any
third-party websites. Your use of third-party websites is at your own risk and
subject to the terms and conditions of use for such sites.

Close
OK


We would like to collect your personal information, some of which may be
considered sensitive personal information, such as health data, through cookies
and similar technologies in order to support our marketing efforts, personalize
the site, and improve its performance. By clicking “Accept All”, you confirm
that we have your consent to collect and process your personal information in
accordance with our Privacy Policy, which may include online targeted and social
media advertising. You can personalize your specific preferences by clicking
“Your Privacy Choices”.
Your Privacy Choices Accept All


The Global Privacy Signal that you have set in your devices browser has been
recognized.


 * YOUR PRIVACY CHOICES


 * TARGETING & SOCIAL MEDIA COOKIES


 * STRICTLY NECESSARY COOKIES


 * FUNCTIONAL COOKIES


 * PERFORMANCE COOKIES

YOUR PRIVACY CHOICES



This website may use cookies as described in the categories on this page. By
default, all cookie categories are ‘on’. Strictly Necessary cookies are ‘always
active’ and may not be turned off. You may alter your cookie preferences for
this website using the ‘on/off’ toggles and confirming your choices, or by using
the buttons on the bottom of this page. Additional information about the
company’s privacy practices can be found here Privacy Policy.

To exercise other rights as may be allowed by state laws, please complete the
form found here Data Subject Request Form.




TARGETING & SOCIAL MEDIA COOKIES

Targeting & Social Media Cookies


To personalize your specific preferences, use the toggle to turn the cookies
"on" or "off".

 * TARGETING COOKIES
   
   Switch Label label
   
   These cookies may be set through our site by our advertising partners. They
   may be used by those companies to build a profile of your interests and show
   you relevant advertisements on other sites. They do not store directly
   personal information, but are based on uniquely identifying your browser and
   internet device. If you do not allow these cookies, you will experience less
   targeted advertising.

 * SOCIAL MEDIA COOKIES
   
   Switch Label label
   
   These cookies are set by a range of social media services that we have added
   to the site to enable you to share our content with your friends and networks
   (such as Facebook, Twitter, LinkedIn). They are capable of tracking your
   browser across other sites and building up a profile of your interests. This
   may impact the content and messages you see on other websites you visit. If
   you do not allow these cookies you may not be able to use or see these
   sharing tools.

STRICTLY NECESSARY COOKIES

Always Active

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
that amount to a request for services, such as setting your privacy preferences,
logging in, or filling in forms. You can set your browser to block or alert you
about these cookies, but blocking these cookies will prevent the site from
working. These cookies do not store any personal information.

FUNCTIONAL COOKIES

Functional Cookies


These cookies enable our websites to provide enhanced functionality and
personalization. They may be set by us or by third party service providers whose
services we have added to our pages. If you reject these cookies, then some or
all of these services may not function properly.

PERFORMANCE COOKIES

Performance Cookies


These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. We may collect
your session ID, IP address, device identifiers, and your activity with the
website. We may provide these cookies to third party service providers to help
us run these analytics. If you block or opt out of these cookies, we will not
know when you have visited our site, and will not be able to monitor its
performance.

If you are located in Europe, the personal data may be sent to a country (e.g.
United States) that has not been deemed to provide an adequate level of data
protection or appropriate safeguards. By accepting these cookies, you consent to
the data processing for analytics purposes and to the transfer of your personal
data to the United States each time you visit our site.



Back Button


COOKIE LIST

Filter Button
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Clear
checkbox label label
Apply Cancel
Confirm My Cookie Choices
Reject All Cookies Allow All Cookies




Feedback